

**Gemphire Therapeutics to Report Third Quarter Financial Results and Corporate Update on November 2;
Corporate Presentation at the 25th Annual Credit Suisse Healthcare Conference on November 7**

October 26, 2016 4:02 PM ET

LIVONIA, Mich., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia and NAFLD/NASH (nonalcoholic fatty liver disease), today announced that it will issue a press release announcing financial results for the third quarter ended September 30, 2016 on Wednesday, November 2.

The Company also announced that Mina Sooch, Gemphire's CEO, will be presenting at the 25th Annual Credit Suisse 2016 Healthcare Conference, being held at the Phoenician Hotel in Scottsdale, Arizona, November 7-8.

25th Annual Credit Suisse Healthcare Conference Presentation Details:

Date: Monday, November 7
Time: 10:00am Mountain Time/12:00pm Eastern Time
Location: Phoenician Hotel, Ballroom G

The presentation slides will be available immediately prior to and for 90 days following the presentation on the Investors and Media page of Gemphire's website at <http://ir.gemphire.com>.

About Gemphire

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and NAFLD/NASH (nonalcoholic fatty liver disease). Please visit www.gemphire.com for more information.

Contact:
Andrew McDonald, Ph.D.
LifeSci Advisors, LLC
(646) 597-6987

Jeff Mathiesen, CFO
Gemphire Therapeutics
(734)-245-1700



Gemphire Therapeutics